Keros Therapeutics Stock Plunges 81% in 3 Months: Here's Why

Keros Therapeutics Stock Performance - Keros Therapeutics (KROS) shares have plunged 80.9% in the past three months and 79.8% over the past year, significantly underperforming the industry's 12% decline [1][4] Cibotercept (KER-012) Clinical Trial Update - The company voluntarily halted dosing in the mid-stage TROPOS study of cibotercept (KER-012) for pulmonary arterial hypertension (PAH) due to unexpected adverse pericardial effusion events [1][2] - Initially suspended dosing in the 3 mg/kg and 4.5 mg/kg treatment arms, later extended to include the 1.5 mg/kg and placebo arms [3] - The TROPOS study is being concluded ahead of schedule, with top-line data expected in Q2 2025 [5] Other Pipeline Candidates - Elritercept (KER-050) is in two ongoing phase II studies for myelodysplastic syndromes (MDS) and myelofibrosis, with a planned phase III RENEW study for transfusion-dependent anemia [8][9] - KER-065 is in phase I development for obesity and neuromuscular diseases, with top-line data expected in Q1 2025 and a proof-of-concept study planned in obese patients [10] Industry Comparison - Castle Biosciences (CSTL) shares have declined 16.3% in three months, with 2024 earnings estimates increasing from 34 to 39 cents per share [12] - BioMarin Pharmaceutical (BMRN) shares have lost 11.9% in three months, with 2024 earnings estimates improving from $3.28 to$3.29 per share [13] - CytomX Therapeutics (CTMX) shares have declined 22.4% in three months, with 2024 loss estimates remaining at 5 cents per share [14]